AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by ...

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in ...

INDICATIONS AND USAGE AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s ...

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in CashRepresents a 139.7% premium to most recent ...
The Malaysian Reserve

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with ...

Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells

Kanazawa University, report in ACS Applied Nano Materials a new method to precisely measure nuclear elasticity—the stiffness ...

Magnetoelectric nanotherapy shrinks pancreatic tumors and extends survival in preclinical study

A new study has found for the first time that magnetoelectric nanoparticles—tiny, wirelessly controlled particles activated ...